NCT00891384 is a Phase 3 clinical trial of Lenalidomide in Multiple Myeloma, sponsored by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH.

Who is sponsoring NCT00891384?

NCT00891384 is sponsored by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH.

What drugs are being tested in NCT00891384?

Interventions in NCT00891384: Lenalidomide, Lenalidomide.

What condition does NCT00891384 study?

NCT00891384 studies Multiple Myeloma.

Is NCT00891384 still recruiting?

NCT00891384 is currently completed. Last updated 19 January 2018.

Last reviewed 2018-01-19 · How we verify

NCT00891384

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Completed Phase 3 Last updated 19 January 2018

What this trial tests

Phase 3 trial testing Lenalidomide in Multiple Myeloma in 194 participants. Completed in 22 June 2017.

Timeline

1 April 2009

Primary endpoint
22 June 2017

22 June 2017

Quick facts

Lead sponsor	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	194
Start date	1 April 2009
Primary completion	22 June 2017
Estimated completion	22 June 2017
Sites	5 locations across Germany

Drugs / interventions tested

Lenalidomide — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH — full company profile →

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation as first line therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).
Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, et al · · 2023 · PMID 37958331 · DOI 10.3390/cancers15215157

Verify or expand the search:

Other trials of Lenalidomide

Trials testing the same drug.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07247097 — ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred · Phase 2 · not yet recruiting
NCT07465029 — A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting
NCT06910124 — Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Neg · Phase 2 · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH trials

Trials by the same sponsor.

NCT02335268 — Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thr · Phase 2 · completed
NCT03622931 — Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines · Phase 2 · terminated
NCT01509560 — PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-ho · Phase 2 · completed
NCT01320111 — Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment · Phase 2 · completed
NCT01081431 — Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPS · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00891384 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Last refreshed: 19 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00891384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing